Amag Pharmaceuticals Inc (NASDAQ:AMAG) Has Decline in Shorts

October 2, 2018 - By Ash

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Logo

Investors sentiment increased to 1.45 in Q2 2018. Its up 0.61, from 0.84 in 2018Q1. It improved, as 16 investors sold AMAG Pharmaceuticals, Inc. shares while 42 reduced holdings. 26 funds opened positions while 58 raised stakes. 43.35 million shares or 15.69% more from 37.48 million shares in 2018Q1 were reported.
Mason Street Advsr Limited Liability Com reported 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Jpmorgan Chase & Commerce has 0.01% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 1.40 million shares. State Of Alaska Department Of Revenue reported 0% stake. Connecticut-based Hartford Inv Management has invested 0.01% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Alps Advsr owns 53,767 shares or 0% of their US portfolio. D E Shaw & Comm stated it has 1.01 million shares. Rocky Mountain Advisers Limited Company stated it has 0.22% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Secor Capital Ltd Partnership holds 45,530 shares or 0.08% of its portfolio. Amer International Group Inc invested in 0% or 26,442 shares. Ironwood Investment Management Lc stated it has 0.47% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Pinebridge Invests Limited Partnership reported 0.03% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Alliancebernstein Limited Partnership invested in 64,363 shares. Hbk Invests Limited Partnership holds 33,400 shares or 0.01% of its portfolio. Metropolitan Life Insurance Company New York accumulated 0% or 12,656 shares. Moreover, Geode Capital Mngmt Ltd Liability Com has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Since June 4, 2018, it had 0 insider buys, and 1 insider sale for $500,000 activity.

The stock of Amag Pharmaceuticals Inc (NASDAQ:AMAG) registered a decrease of 1.15% in short interest. AMAG’s total short interest was 10.26 million shares in October as published by FINRA. Its down 1.15% from 10.38 million shares, reported previously. With 399,100 shares average volume, it will take short sellers 26 days to cover their AMAG’s short positions. The short interest to Amag Pharmaceuticals Inc’s float is 39.46%.

The stock increased 0.90% or $0.18 during the last trading session, reaching $20.18. About 360,311 shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 14.53% since October 2, 2017 and is uptrending. It has underperformed by 1.09% the S&P500.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. The company has market cap of $695.66 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Among 4 analysts covering Amag Pharmaceuticals (NASDAQ:AMAG), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Amag Pharmaceuticals had 9 analyst reports since May 3, 2018 according to SRatingsIntel. The stock has “Buy” rating by FBR Capital on Monday, August 6. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Neutral” rating by Janney Capital on Friday, June 15. The firm earned “Hold” rating on Thursday, May 3 by Cantor Fitzgerald. The firm has “Neutral” rating by Cantor Fitzgerald given on Monday, August 6. Cantor Fitzgerald maintained it with “Hold” rating and $1700 target in Sunday, June 17 report. The stock has “Buy” rating by FBR Capital on Friday, June 15. The firm has “Hold” rating by Cantor Fitzgerald given on Monday, June 25. Cantor Fitzgerald maintained the shares of AMAG in report on Monday, June 4 with “Hold” rating. Leerink Swann initiated AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Monday, May 21 with “Hold” rating.

More recent AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) news were published by: Nasdaq.com which released: “AMAG Pharmaceuticals Partners With Emmy-Nominated Actress Cheryl Hines and Dr. Marla Shapiro to Start a …” on September 20, 2018. Also Nasdaq.com published the news titled: “AMAG Pharmaceuticals Pays Off $475 Million of Senior Secured Notes” on September 06, 2018. Nasdaq.com‘s news article titled: “AMAG Pharmaceuticals Acquires Orphan Drug Candidate for Treatment of Severe Preeclampsia” with publication date: September 26, 2018 was also an interesting one.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>